Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02670785 · ClinicalTrials.gov registry record · Phase 2

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

A Phase 2 study of Menopause and Dyspareunia, sponsored by Warner Chilcott.

Completed
Registry status
Phase 2
Development phase
203
Enrollment target
20
Study locations

NCT02670785: Completed Phase 2 study of Menopause and Dyspareunia, sponsored by Warner Chilcott.

NCT02670785 is a Phase 2 study of Menopause and Dyspareunia that has completed, run by Warner Chilcott. The registered enrollment target is 203 participants, below the 9,390-participant average among 54 other Menopause trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02670785, a Phase 2 study of Menopause and Dyspareunia, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
Phase 2
Development phase
203 participants
Enrollment target
20
Study locations

Study Summary

This study will access the safety and efficacy of three doses of estradiol vaginal capsules in postmenopausal women with vulvovaginal atrophy.

Interventions

  • DRUG Placebo
  • DRUG Estradiol Vaginal Capsule (EVC)

Study Locations (20)

Florida

  • Women's Medical Research Group, LLC - Clearwater
  • Radiant Research, Inc. - Pinellas Park
  • Comprehensive Clinical Trials, LLC - West Palm Beach

North Carolina

  • Carolina Women's Research and Wellness Center - Durham
  • Hawthorne Medical Research, Inc. - Winston-Salem

Ohio

  • Rapid Medical Research, Inc. - Cleveland
  • Women's Health Research - Columbus

Texas

  • Radiant Research, Inc. - Dallas
  • Radiant Research, Inc. - San Antonio

Washington

  • Seattle Women's Health, Research, Gynecology - Seattle
  • North Spokane Women's Clinic - Spokane

Arizona

  • Visions Clinical Research-Tucson - Tucson

California

  • Genesis Center for Clinical Research - San Diego

Connecticut

  • Coastal Connecticut Research, LLC - New London

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2016-02-15
Est. Completion 2016-11-14
Phase Phase 2
Warner Chilcott

53 total trials

What the finished NCT02670785 record still lists

NCT02670785 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 9,390-participant average among 54 other Menopause trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02670785 names 20 study sites across 14 states, led by Florida, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT02670785 about?

NCT02670785 is a clinical study titled "A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy". This study will access the safety and efficacy of three doses of estradiol vaginal capsules in postmenopausal women with vulvovaginal atrophy.

What is the current status of trial NCT02670785?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2016-02-15. Estimated completion is 2016-11-14.

What conditions does trial NCT02670785 study?

This clinical trial studies the following conditions: Menopause, Dyspareunia, Vulvovaginal Atrophy.

What interventions are being tested in trial NCT02670785?

The interventions under investigation include: Placebo (DRUG), Estradiol Vaginal Capsule (EVC) (DRUG).

Who is sponsoring clinical trial NCT02670785?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02670785 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02670785's enrollment target sits among peer trials

203 8th of 54 higher than 47 of 54 other Menopause trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05652686 · 203 participants · Phase 1

    A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • NCT06063122 · 203 participants · NA

    Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

  • NCT07031245 · 203 participants · NA

    Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02670785, the US trial registry maintained by the National Library of Medicine. NCT02670785 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.